 | |
| Company type | Private |
|---|---|
| Industry | Biotechnology,Biopharmaceuticals |
| Founded | 1953; 73 years ago (1953) |
| Founder | Datla Venkata Krishnam Raju |
| Headquarters | Jubilee Hills, Hyderabad, Telangana, India |
Key people | Mahima Datla (CEO and Managing Director)[1] |
| Revenue |  ₹3,820 crore (US$450 million) (FY23)[2] |
| ₹953 crore (US$110 million) (FY23)[2] | |
Number of employees | 2,500 |
| Website | www |
Biological E Limited is an Indianbiotechnology andbiopharmaceutical company based inHyderabad, Telangana. It specialises in the areas of low-cost vaccine production.[3]
The company was founded by Dr. D.V.K. Raju and Mr. G.A.N. Raju in 1953 as Biological Products Private Limited. It was among the first private sector companies in India to manufacture biological products.[4] It pioneered Heparin production in India.[5]
In 1964, Evans Medicals, a U.K. based Pharma Company, which later got merged with Glaxo SmithKline acquired 40% stake in the company, which was subsequently bought back by the promoters in 1995.[citation needed]
During the 1960s and 70s, Biological E developed formulations in cough and digestive enzymes, started manufacturing anti-tetanus serum, and launched anti-TB drugs, TT and DTP vaccines.[5]
Biological E embarked specialise in low-cost vaccines manufacturing. The company started manufacturing its flagship vaccine product, Pentavalent (DTP Hib HepB) in 2008.[5] Biological E is a major supplier of vaccines to international development and aid organisations such asWHO,UNICEF,BMGF.[5]
During theCOVID-19 pandemic, the company signed a pact withBaylor College of Medicine,Texas Children's Hospital and Dynavax Technologies to develop aCOVID-19 vaccine.[6][7] The vaccine Corbevax[8]/Bio E COVID-19 was expected to roll out in 2021 with 75 to 80 million doses manufactured per month; the production was expected to reach 1 billion doses by the end of 2022 under theQuad initiative.[9][10]
In August 2020, the company signed a deal withJohnson & Johnson to manufacture the latter's vaccine candidate at its Hyderabad facility.[11] In February 2021, it announced that it would produce over 600 million doses of the single-doseJanssen vaccine annually.[12][13]
This article incorporates text from this source, which is in thepublic domain.